Mouse hemithoracic irradiation and its interaction with cytotoxic drugs.
Irradiation of the mouse right or left hemithorax at 14 or 18 Gy produced a dose-dependent rise in breathing rate 16 weeks after irradiation without significant mortality. The measurement of breathing rate changes following right hemithoracic irradiation combined with the maximally tolerated dose of cytotoxic drugs was assessed as a method for qualitatively detecting drug-irradiation interactions which either exacerbate pneumonitis or alter its time course. Cyclophosphamide at 100 mg/kg accentuated and accelerated the rise in breathing rate, culminating in early mortality. BCNU 30 mg/kg delayed the appearance of the radiation response. Busulphan 30 mg/kg appeared to be radioprotective, but this was shown to be due to the DMSO-containing vehicle. Doxorubicin 6 mg/kg had no effect when combined with right or left hemithoracic irradiation. Carboplatin 100 mg/kg, vindesine 4 mg/kg and vinblastine 4 mg/kg had no substantial effect upon the changes in breathing rate.
Lockhart
S P
SP
Radiotherapy Research Unit, Institute of Cancer Research, Sutton, Surrey, UK.
Down
J D
JD
Steel
G G
GG
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D008168:Lung / Q000187:drug effects* / Q000528:radiation effects*; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D010996:Pleural Effusion / Q000209:etiology; D011014:Pneumonia / Q000209:etiology; D011829:Radiation Dosage; D012119:Respiration / Q000528:radiation effects; D013909:Thorax / Q000528:radiation effects*; D013997:Time Factors
D000970:Antineoplastic Agents; D004317:Doxorubicin